Clovis Oncology, Inc. filed a notice for the selection of Successful Bidder in the US Bankruptcy Court for the sale of its certain assets on March 31, 2023. As a result of the auction conducted on March 30, 2023, pharma& Schweiz GmbH, for a total net present value purchase price of $116 million, has been selected as the winning bidder and Dr. Reddy's Laboratories, Inc. for a total net present value purchase price of $107.5 million has been selected as the backup bidder for the sale of debtor's certain assets The debtor's assets include substantially all of the assets relating to the FAP Therapeutic Assets.
Clovis Oncology, Inc.
Equities
CLVS.Q
US1894641000
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |